What is the recommended dosing and administration protocol for diltiazem (Cardizem) in a hemodynamically stable patient with narrow‑complex supraventricular tachycardia when adenosine is contraindicated, including bolus dose, infusion rates, contraindications, and monitoring requirements?

Diltiazem (Cardizem) for Narrow-Complex SVT When Adenosine is Contraindicated

For hemodynamically stable patients with narrow-complex supraventricular tachycardia when adenosine is contraindicated (such as in asthma), administer diltiazem 15-20 mg (0.25 mg/kg) IV over 2 minutes, followed by a second dose of 20-25 mg (0.35 mg/kg) in 15 minutes if needed, then maintain with a continuous infusion of 5-15 mg/hour titrated to heart rate. 1, 2

Initial Bolus Dosing

• First dose: 15-20 mg (0.25 mg/kg) IV administered over 2 minutes 1, 2
• Second dose (if needed): 20-25 mg (0.35 mg/kg) IV given 15 minutes after the first dose if rhythm persists 1, 2
• The 2016 ACC/AHA/HRS guidelines specify 0.25 mg/kg for initial dosing, which translates to approximately 15-20 mg for most adults 2

Maintenance Infusion

After successful conversion or rate control:

• Infusion rate: 5-15 mg/hour, titrated to heart rate 1, 2
• Start at 5-10 mg/hour and increase up to 15 mg/hour as needed for rate control 2

Absolute Contraindications

Do not administer diltiazem if the patient has: 2

• Second- or third-degree AV block (unless pacemaker present)
• Sick sinus syndrome or symptomatic bradycardia (unless pacemaker present)
• Decompensated systolic heart failure or significant LV dysfunction
• Hypotension (systolic BP typically <90 mmHg)
• Cardiogenic shock
• Pre-excited atrial fibrillation/flutter (WPW syndrome) - this is critical as AV nodal blockers can accelerate ventricular response and cause hemodynamic collapse 1
• Wide-complex tachycardia of uncertain etiology

Critical Monitoring Requirements

During Administration:

• Continuous cardiac monitoring with 12-lead ECG capability 2
• Blood pressure monitoring every 2-5 minutes during bolus administration and for 20 minutes after 3, 4
• Immediate defibrillator availability - diltiazem may rarely convert SVT to a more malignant rhythm 1

Expected Hemodynamic Changes:

• Systolic BP typically drops 7-13 mmHg initially but usually returns to baseline within 20 minutes 3, 4
• Hypotension requiring intervention occurs in <1% of patients with slow infusion 4

Post-Conversion Monitoring:

• Continue cardiac monitoring for at least 2 hours 4
• Monitor for recurrence of tachycardia
• Watch for bradycardia or heart block

Efficacy and Clinical Pearls

Diltiazem demonstrates superior efficacy compared to adenosine in multiple studies:

• Conversion rates: 95-98% with diltiazem versus 60-87% with adenosine 5, 6, 4, 7
• The 2015 study by Demircan found 95% conversion with diltiazem 0.25 mg/kg versus 72% with adenosine 5
• A 2009 multicenter trial showed 98% conversion with slow-infusion calcium channel blockers versus 86.5% with adenosine 4

Important clinical considerations:

• Slow infusion is key to safety - rapid bolus administration increases hypotension risk 4
• If the first bolus fails, the second bolus (given 15 minutes later) succeeds in approximately 50% of remaining cases 6
• Diltiazem effectively rescues 35-77% of cases that fail adenosine 7
• Time to conversion averages 6-8 minutes, slightly longer than adenosine (3 minutes) but with higher overall success 3, 7

Drug Interactions and Precautions

Avoid combining with other AV nodal blockers:

• Do not give diltiazem after recent beta-blocker administration - profound bradycardia can occur due to overlapping effects 1
• The short half-life of adenosine allows safe follow-up with diltiazem, but the reverse is dangerous 1

Hepatic/Renal Dysfunction:

• Use with caution and consider dose reduction in hepatic or renal impairment 2
• Diltiazem is a CYP3A4 substrate and moderate inhibitor 2

Common Pitfalls to Avoid

1. Never use in wide-complex tachycardia unless you are absolutely certain it is supraventricular with aberrancy - verapamil/diltiazem can cause cardiovascular collapse in ventricular tachycardia 1, 8, 9

2. Do not use in pre-excited AF/flutter - this can accelerate ventricular response through the accessory pathway and precipitate ventricular fibrillation 1

3. Avoid rapid bolus administration - infuse over the full 2 minutes to minimize hypotension 1, 4

4. Do not use in decompensated heart failure - negative inotropic effects can worsen cardiac output 2

5. Have resuscitation equipment ready - though rare, severe adverse events including cardiac arrest have been reported with calcium channel blockers 1

Alternative Considerations

If diltiazem is also contraindicated or unavailable:

• Beta-blockers (esmolol, metoprolol) are reasonable alternatives with Class IIa recommendation 1
• Synchronized cardioversion remains the definitive treatment for hemodynamically unstable patients 8

The 2025 AHA guidelines continue to support diltiazem as a highly effective option for stable narrow-complex tachycardia, with conversion rates of 64-98% 8.